Neuroanatomy of Anxiety: A Brief Review

Cameron K. Schmidt ¹, Shehzad Khalid ², Marios Loukas ², R. Shane Tubbs ³

¹. Clinical Anatomy, Seattle Science Foundation  ². Department of Anatomical Sciences, St. George’s University School of Medicine, Grenada, West Indies  ³. Neurosurgery, Seattle Science Foundation

Corresponding author: Cameron K. Schmidt, cameronkurtschmidt@gmail.com

Abstract

Anxiety disorders are among the most prevalent psychological issues worldwide, displaying the youngest age of onset and greatest chronicity of any mood or substance abuse disorder. Given the high social and economic cost imposed by these disorders, developing effective treatments is of the utmost importance. Anxiety disorders manifest in a variety of symptomatic phenotypes and are highly comorbid with other psychological diseases such as depression. These facts have made unraveling the complex underlying neural circuitry an ever-present challenge for researchers. We offer a brief review on the neuroanatomy of anxiety disorders and discuss several currently available therapeutic options.

Introduction And Background

Anxiety is understood as an adaptive response, serving to maximize survival through the avoidance of potentially harmful events [1]. In unraveling the complexities of anxiety, it is important to distinguish anxiety from fear. Fear is a response triggered by the presence of an imminent, real threat, whereas anxiety revolves around the anticipation of potential harm in the future [2]. While anxiety is a necessary tool for human cognition, anxiety disorder describes the uncontrolled, excessive persistence of anxious responses such that an individual is no longer able to live a normal functioning life.

The lifetime prevalence of anxiety disorders is estimated to be from 11.3% to 14.7% worldwide [3]. Epidemiologic data from the World Health Organization (WHO) estimates the lifetime prevalence for anxiety disorders to be 25% in the United States [4]. As of 2010, anxiety disorders were the most common mental disorder in the European Union, estimated to have an annual cost of 74.4 billion euros [5].

The prevalence of anxiety disorders varies by culture, with rates in Euro/Anglo cultures almost double what they are in African cultures [6]. Prevalence rates vary too by gender, with women having a statistically greater likelihood than men of developing an anxiety disorder at some point in their lives [3]. Finally, and perhaps most importantly, anxiety disorders display the youngest age of onset and greatest chronicity of any mood or substance abuse disorders [4].

Given the early age of onset, chronicity, and high rate of comorbidity associated with anxiety disorders, early interventions may prevent the development of many secondary disorders. With the high social and economic cost imposed by anxiety disorders, the development of effective treatments is paramount.

We briefly review the functional neuroanatomy of anxiety and discuss the effects of several therapeutic interventions on neural functioning (see Etkin, et al. for further reading) [7].

Review

The term ‘anxiety disorders’ describes a range of multidimensional phenotypes. Many traits are shared across anxiety disorders. However, key differences exist in underlying cognitive processes that remain to be untangled.

Functional imaging of anxiety disorders

The phenotypic heterogeneity of anxiety disorders is reflected in the heterogeneity of the neuroimaging literature. To take one example, anxiety and depression are highly comorbid [8] and their co-occurrence is known to drive unique brain activation patterns [9]. It is also known that different types of anxiety disorders yield different activation patterns, yet how each of these anxiety disorders subtypes vary when comorbid with depression has not been untangled.

However, we do know that common to three major types of anxiety disorders (post-traumatic stress disorder (PTSD), social anxiety disorder (SAD), and specific phobias (e.g., arachnophobia)) is hyperactivation of the amygdala and insula [10].
The amygdala is one of the most consistently identified regions of hyperactivity in anxiety [11] with its interactional behavior varying across anxiety disorder subtypes [10]. The amygdala serves several major roles including reward learning, unpredictability processing, salience determination in the setting of emotional and social stimuli, and broader stimulus valuation [11-12]. It is theorized that amygdalar dysfunction may drive the inappropriate threat perception and emotional dysregulation believed to lie at the heart of many anxiety disorders.

The clinical manifestation of anxiety is often preceded by what is known as an anxious temperament (AT). Rhesus monkeys are a well-validated primate model of AT and 18-fluorodeoxyglucose positron emission tomography (FDG-PET) in young rhesus macaques has shown that activity in the lateral division of the central nucleus (CeL) of the dorsal amygdala and in the anterior hippocampus predicts all examined measures of AT [13].

Of interest, the fusiform gyrus appears to hold significant influence over the amygdala in the emotional face-processing of SAD patients. The effect is most profound for viewing fearful faces and, within this condition, activation of the fusiform gyrus was negatively correlated with social anxiety scores and other avoidance-related behavioral assessments [14].

Inappropriately severe and prolonged anticipation of negative events is posited as a common cognitive problem in anxiety disorders. The anticipation of negative outcomes (e.g., aversive pictures) recruits a neural network that includes the anterior cingulate cortex (ACC), insula, amygdala, dorsolateral prefrontal cortex (dPFC), parahippocampal gyrus, and the medial aspects of the bilateral orbitofrontal cortex (OFC) [15-16].

The ACC, together with the insula, are increasingly understood to constitute a "fear network" [17]. Among other functions, ACC is involved in conflict-monitoring and fear learning. Functional magnetic resonance imaging (fMRI) investigation has shown trait-anxiety levels to be inversely correlated with task-related rostral ACC (rACC) activation when viewing affective faces [18]. Trait anxiety has also been correlated positively with ACC activation and negatively with functional connectivity between the ACC and lateral PFC (lPFC) in an emotional conflict task [19].

The insula is thought to play a significant role in the dysfunctional anticipatory processing of anxious individuals [20], which is unsurprising given its role in effective and interoceptive processing [21]. Compared to anxiety-normative (AN) controls, anxiety-prone (AP) individuals demonstrate greater bilateral insular activation during the anticipation of aversive stimuli (pictures of snakes and spiders). This abnormal insular activation is associated with reduced activation of the superior and medial frontal gyri [20]. Other analyses have specified the right anterior insula (AI) and the left dPFC to be regions of heightened activity in the anticipation of aversive stimuli in AP patients, with measures of anxiety correlating with greater activation of the amygdala and AI in response to emotional faces [8].

Abnormal anticipatory processing has also been attributed to hyperactivation of the right amygdala and the bed nucleus of the stria terminalis (BNST) [16]. In children with a generalized anxiety disorder (GAD), hyperactivity in the right amygdala during anticipation of aversive images was positively correlated with symptom severity [22].

The PFC is another region of interest in anxiety disorders. Among several roles, the ventrolateral PFC (vPFC) is known to be activated upon the presentation of emotional distractors during a working memory task [23]. Examination of SAD patients found hypoactivation of the vPFC in a verbal fluency task, with a negative correlation between vPFC activation and social avoidance [24].

Researchers at Cambridge found that lesions of the vPFC in the common marmoset result in increased anxiety characteristics [25]. The same research group found that lesions to either the vPFC or the anterior OFC result in increased anxiety-related responses to a mock snake [26].

Among the attentional deficits that define anxiety disorders, anxious individuals show an attentional bias (AB) towards threat, with increased vigilance toward threatening stimuli and a decreased ability to disengage from said threats during visual search tasks [27]. Transcranial direct current stimulation (tDCS) of the right dPFC has been shown to induce attentional impairments similar to those noted in emotional disorders such as anxiety, suggesting a causal role of the dPFC in anxiety disorders [28]. Meanwhile, anodal tDCS over the left dPFC significantly decreases the attentional bias for social threat associated with SAD [29].

As previously mentioned, anxiety disorder subtypes display different patterns of brain activation. One such difference lies in PTSD patients. Etkin and colleagues showed PTSD patients demonstrate both regional hypo- and hyperactivity, while SAD and specific phobia patients only showed regional hyperactivity. In comparison to SAD and specific phobia individuals, PTSD patients have significant hypoactivation in the medial PFC (mPFC), rACC and dorsal ACC (dACC), and thalamus. SAD and specific phobia individuals showed more common hyperactivation in the amygdala and insula [10]. However, it was only in PTSD that amygdalar activation was positively associated with symptom severity [30]. mPFC activity [31], and more
specifically, ventromedial PFC (vmPFC) activity were also found to positively correlate with symptom severity in PTSD [30].

Obsessive-compulsive disorder (OCD) is characterized by obsessive thought patterns and compulsions (e.g., hand-washing, tapping) that becomes debilitating to a patient’s ability to live a normal life. Increased resting OFC and ACC activation has been observed in OCD [32] and anxiety symptoms correlate with ACC hyperactivity [33].

A final distinction of note has been drawn between anxious apprehension (worry) and anxious arousal (somatic anxiety). Engels, et al. describe anxious apprehension as being akin to worry or anticipatory anxiety, with anxious arousal more resembling fear or panic [9]. This distinction has been demonstrated via neuroimaging, with greater right frontal activity associated with anxious apprehension and the contralateral side with anxious arousal [34]. Specifically, anxious apprehension is associated with greater activation in the left IFG and inferior temporal gyrus (ITG), while anxious arousal is associated with less leftward IFG asymmetry. When presented with negative emotion words, individuals with anxious arousal demonstrate greater right-hemisphere temporoparietal activity [35].

**Therapeutic interventions for anxiety disorders**

*Pharmacological therapies*

Selective serotonin reuptake inhibitors (SSRI), serotonin-noradrenaline reuptake inhibitors (SNRI), and benzodiazepines are among the most typical pharmacological treatments for anxiety disorders. SSRIs and SNRIs work by inhibiting reuptake pumps on the membrane of presynaptic neurons, increasing the amount of serotonin and norepinephrine in the synaptic cleft available for post-synaptic action.

Citalopram, an SSRI, has been shown to influence neural changes in anxiety disorder patients [36], driving the attenuation of the lateral OFC and right amygdala to aversive faces [37]. Three weeks of escitalopram, another SSRI, decreased activation of the bilateral posterior and middle insula and the mPFC during aversive anticipation [38]. Of interest, pre-treatment activation of the ACC to neutral and aversive stimuli is associated with greater reductions in anxiety after eight weeks of treatment with venlafaxine (SNRI) [39].

Pregabalin affects the brain through a mechanism that ultimately leads to, among other things, the upregulation of GABA, an inhibitory neurotransmitter. Treatment with pregabalin has been shown to attenuate activation of the left amygdala and anterior insula and increases in ACC activation during the anticipation and processing of emotional images [40].

*Psychological therapies*

Among many therapeutic psychological programs, cognitive behavioral therapy (CBT) has been gaining traction in response to significant outcomes associated with the treatment. In OCD patients, CBT has been shown to induce functional changes in the activation of the putamen, cerebellum and hippocampus [32], subgenual ACC [30], the right head of the caudate nucleus [41], and right dACC [42]. These CBT-driven changes are all correlated with anxiety symptom improvement.

Exposure therapy has traditionally been controversial due to discrepancies in the practitioner’s understanding and utilization of the treatment. That aside, two weeks of exposure to spiders has been shown to reduce hyperactivity in the amygdala, ACC, and insula of phobia-specific anxiety patients [43].

Yet another proposed psychological therapy is mindfulness meditation. Zeidan and colleagues trained participants in mindfulness meditation and then compared the efficacy of the treatment to a control condition in which participants were asked to attend to their breath (ATB). Compared to the ATB group, mindfulness meditation resulted in anxiety relief that correlated with significantly greater activation of the ACC, vmPFC, and AI [44].

**Electrical stimulation therapies**

One characteristic of anxiety disorders is the AB for threat that is known to contribute to the perseverance of the condition. As anodal tDCS over the left dlPFC has been shown to attenuate the maintenance of the AB for threat; tDCS has presented itself as an interesting therapeutic avenue in anxiety disorders [29, 43]. Several reviews of the literature have found evidence for an anxiolytic effect of repetitive transcranial magnetic stimulation (rTMS) [46–48]. The authors do however note the limitations of many of the studies examining rTMS in the context of anxiety, and further research is required for both these treatments.

Deep brain stimulation (DBS) of the BST has been shown to be safe and effective in treating cases of severe, treatment-resistant OCD [49]. The efficacy of such a treatment has also been proved in a rodent model of non-OCD anxiety, where electrical stimulation of the BST was found to reduce the rodent’s contextual anxiety [50]. However, more work is required before DBS may be used on a large scale for anxiety patients.
Conclusions

Owing to the heterogeneous and highly comorbid nature of anxiety disorders, a thorough understanding of the neural underpinnings of the disease remains beyond our reach. As with any complex process, the complexity of regional and network interactions at a neural level, combined with the limitations of our current methodologies, means such an understanding is not on the immediate horizon. However, significant progress has been made in the past two decades towards developing a more robust picture of anxiety disorders. From this work, promising therapies such as DBS, tDCS, and rTMS have emerged and will continue to be refined in the coming years.

Additional Information

Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Gefenso EA, Rosa DS, Fachin AL, Mortari MR, Cunha AO, Beleboni RO: Anxiety: a systematic review of neurobiology, traditional pharmaceuticals and novel alternatives from medicinal plants. CNS Neurol Disord Drug Targets. 2014, 13:150–165.
2. Davis M, Walker DL, Miles L, Grillon C: Phasic vs sustained fear in rats and humans: role of the extended amygdala in fear vs anxiety. Neuropsychopharmacology. 2010, 35:105–135. 10.1038/npp.2009.109
3. Steel Z, Marmane C, Iranpour C, Chey T, Jackson JW, Patel V, Silove D: The global prevalence of common mental disorders: a systematic review and meta-analysis 1980–2013. Int J Epidemiol. 2014, 43:476–493. 10.1093/ije/dyu038
4. Cross-national comparisons of the prevalences and correlates of mental disorders . Bull World Health Organ. 2000, 78:413–426.
5. Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jonsson B: The economic cost of brain disorders in Europe. Eur J Neurol. 2012, 19:155–162. 10.1111/j.1468-1331.2011.03590.x
6. Baxer AJ, Scott KM, Vos T, Whiteford HA: Global prevalence of anxiety disorders: a systematic review and meta-regression. Psychol Med. 2015, 45:897–910. 10.1017/s003329171200147x
7. Etkin A: Functional neuroanatomy of anxiety: a neural circuit perspective. Curr Top Behav Neurosci. 2010, 2:251–277.
8. Stein MB, Simmons AN, Feinstein JS, Paulus MP: Increased amygdala and insula activation during emotion processing in anxiety-prone subjects. Am J Psychiatry. 2007, 164:518–527. 10.1176/ajp.2007.164.2.518
9. Engels AS, Heller W, Spielberg JM, Warren SL, Sutton BP, Banich MT, Miller GA: Co-occurring anxiety influences patterns of brain activity in depression. Cogn Affect Behav Neurosci. 2010, 10:141–156. 10.3758/cabn.10.1.141
10. Etkin A, Wager TD: Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry. 2007, 164:1476–1488. 10.1176/appi.ajp.2007.07030504
11. Holzschneider K, Mulert C: Neuroimaging in anxiety disorders . Dialogues Clin Neurosci. 2011, 13:453–461.
12. Adolphs R: What does the amygdala contribute to social cognition?. Ann N Y Acad Sci. 2010, 1191:42–61. 10.1111/j.1468-1331.2010.05445.x
13. Shackman AJ, Fox AS, Oler JA, Shelton SE, Davidson RJ, Kalin NH: Neural mechanisms underlying heterogeneity in the presentation of anxious temperament. Proc Natl Acad Sci USA. 2013, 110:6145–6150. 10.1073/pnas.1214504110
14. Pujol J, Harrison BJ, Ortiz H, et al.: Influence of the fusiform gyrus on amygdala response to emotional faces in the non-clinical range of social anxiety. Psychol Med. 2009, 39:1177–1187. 10.1017/s003329170999104x
15. Sarinopoulos I, Grue DW, Mackiewicz KL, Herrington JD, Lor M, Steege EE, Nitschke JB: Uncertainty during anticipation modulates neural responses to aversion in human insula and amygdala. Cereb Cortex. 2010, 20:929–940. 10.1093/cercor/bhp155
16. Straube T, Mentzel HJ, Miltenr WH: Waiting for spiders: brain activation during anticipatory anxiety in spider phobics. Neuroimage. 2007, 37:1427–1436. 10.1016/j.neuroimage.2007.06.023
17. Sehmeyer C, Schoning S, Zwitserlood P, Pfleiderer B, Kircher T, Aroti V, Konrad C: Human fear conditioning and extinction in neuroimaging: a systematic review. PloS One. 2009, 4:5865. 10.1371/journal.pone.0005865
18. Klump H, Ho SS, Taylor SF, Phan KL, Abelson JL, Liberzon I: Trait anxiety modulates anterior cingulate activation to threat interference. Depress Anxiety. 2011, 28:194–201. 10.1002/da.20802
19. Comte M, Cancel A, Coull JT, et al.: Effect of trait anxiety on prefrontal control mechanisms during emotional conflict. Hum Brain Mapp. 2015, 36:2207–2214. 10.1002/hbm.22765
20. Simmons A, Strigo I, Matthews SC, Paulus MP, Stein MB: Anticipation of aversive visual stimuli is associated with increased insula activation in anxiety-prone subjects. Biol Psychiatry. 2006, 60:402–409. 10.1016/j.biopsych.2006.04.038
21. Craig AD: How do you feel? Interoception: the sense of the physiological condition of the body . Nature Rev Neurosci. 2002, 3:655–666. 10.1038/nrn9094
22. Monk CS, Telzer EH, Mogk K, et al.: Amygdala and ventrolateral prefrontal cortex activation to masked
angry faces in children and adolescents with generalized anxiety disorder. Arch Gen Psychiatry. 2008, 65:568–576. 10.1001/archpsyc.65.5.568

23. Dolcos F, McCarthy G: Brain systems mediating cognitive interference by emotional distraction. J Neurosci. 2006, 26:2072–2079.

24. Yokoyama C, Kajiy H, Kumano H, et al.: Dysfunction of ventrolateral prefrontal cortex underlying social anxiety disorder: a multi-channel NIRS study. Neuroimage Clin. 2015, 8:455–461. 10.1016/j.nicl.2015.05.011

25. Agustin-Pavon C, Braesicke K, Shiba Y, et al.: Lesions of ventrolateral prefrontal or anterior orbitofrontal cortex in primates heighten negative emotion. Biol Psychiatry. 2012, 72:266–272. 10.1016/j.biopsych.2012.03.007

26. Shiba Y, Kim C, Santangelo AM, Roberts AC: Lesions of either anterior orbitofrontal cortex or ventrolateral prefrontal cortex in marmoset monkeys heighten innate fear and attenuate active coping behaviors to predator threat. Front Syst Neurosci. 2014, 8:250. 10.3389/fnsys.2014.00250

27. Armstrong T, Olatunji BO: Eye tracking of attention in the affective disorders: a meta-analytic review and synthesis. Clin Psychol Rev. 2012, 32:704–723. 10.1016/j.cpr.2012.09.004

28. Sanchez A, Vanderhasse MA, Baeken C, De Raedt R: Effects of tDCS over the right DLPFC on attentional disengagement from positive and negative faces: an eye-tracking study. Cogn Affect Behav Neurosci. 2016, 16:1027–1038.

29. Heeren A, Billieux J, Philippot P, et al.: Impact of transcranial direct current stimulation on attentional bias for threat: a proof-of-concept study among individuals with social anxiety disorder. Soc Cogn Affect Neurosci. 2017, 12:251–260. 10.1093/scan/nsw119

30. Dickens EW, Brunet A, Akervi B, Armony JL: Neural correlates of recovery from post-traumatic stress disorder: a longitudinal fMRI investigation of memory encoding. Neuropsychologia. 2011, 49:1771–1778. 10.1016/j.neuropsychologia.2011.02.055

31. Shin LM, Rauch SL, Pitman RK: Amygdala, medial prefrontal cortex, and hippocampal function in PTSD. Ann NY Acad Sci. 2006, 1071:67–79. 10.1196/annals.1564.007

32. Kang DH, Kwon JS, Kim JJ, et al.: Brain glucose metabolic changes associated with neuropsychological improvements after 4 months of treatment in patients with obsessive-compulsive disorder. Acta Psychiatr Scand. 2005, 107:291–297. 10.1034/j.1600-0447.2005.00070.x

33. Deckersbach T, Dougherty DD, Rauch SL: Functional imaging of mood and anxiety disorders. J Neuropsychiatry. 2006, 16:1–10. 10.1177/1040123005014747

34. Nitschke JB, Heller W, Palmieri PA, Miller GA: Contrasting patterns of brain activity in anxious apprehension and anxious arousal. Psychophysiology. 1999, 36:628–637.

35. Engels AS, Heller W, Mohanty A, Herrington JD, Banich MT, Webb AG, Miller GA: Specificity of regional brain activity in anxiety types during emotion processing. Psychophysiology. 2007, 44:352–363. 10.1111/j.1469-8986.2007.00518.x

36. Hoehn-Saric R, Schland MW, Wong SH: Effects of citalopram on worry and brain activation in patients with generalized anxiety disorder. Psychiatry Res. 2004, 131:11–21. 10.1016/j.psychres.2004.02.003

37. Del-Ben CM, Deakin JF, McKie S, et al.: The effect of citalopram pretreatment on neuronal responses to neurophysiological tasks in normal volunteers: an FMRI study. Neuropsychopharmacology. 2005, 30:1724–1734. 10.1038/sj.npp.1300728

38. Simmons AN, Arce E, Lovero KL, Stein MB, Paulus MP: Subchronic SSRI administration reduces insula response during affective anticipation in healthy volunteers. Int J Neuropsychopharmacol. 2009, 12:1089–1020. 10.1017/s1475921409001469

39. Nitschke JB, Sarinopoulos I, Oathes DJ, Johnstone T, Whalen PJ, Kalin NH: Anticipatory activation in the amygdala and anterior cingulate in generalized anxiety disorder and prediction of treatment response. Am J Psychiatry. 2009, 166:302–310. 10.1176/appi.ajp.2008.07101682

40. Aupperle RL, Tankersley D, Ravindran LN, Flagan T, Stein NR, Paulus MP: Effects of citalopram on worry and brain activation in patients with generalized anxiety disorder. Psychosomatic Medicine. 2007, 69:624–632. 10.1093/psycho/69.6.624

41. Nakatani E, Nakagawa A, Ohara Y, et al.: Effects of behavior therapy on regional cerebral blood flow in obsessive-compulsive disorder. Psychiatry Res. 2005, 124:113–120.

42. Saxena S, Gorbis E, O’Neill J, et al.: Rapid effects of brief intensive cognitive-behavioral therapy on brain glucose metabolism in obsessive-compulsive disorder. Mol Psychiatry. 2009, 14:197–205. 10.1038/sj.mp.4002154

43. Goossens L, Sunaert S, Peeters R, Grieb EJ, Schruers KR: Amygdala hyperfunction in phobic fear normalizes after exposure. Biol Psychiatry. 2007, 62:1119–1125. 10.1016/j.biopsych.2007.04.024

44. Zeidan F, Martinetti KD, Kraft RA, McClaffry JG, Coghill RC: Neural correlates of mindfulness meditation-related anxiety relief. Soc Cogn Affect Neurosci. 2014, 9:751–759. 10.1093/scan/nst041

45. Heeren A, Baeken C, Vanderhasse MA, Philippot P, de Raedt R: Impact of anodal and cathodal transcranial direct current stimulation over the left dorsolateral prefrontal cortex during attention bias modification: an eye-tracking study. PLoS One. 2015, 10:0124182. 10.1371/journal.pone.0124182

46. Zwanzger P, Faggittger AJ, Zavorotynny M, Padberg F: Anxiolytic effects of transcranial magnetic stimulation—an alternative treatment option in anxiety disorders. J Neural Transm (Vienna). 2009, 116:767–775.

47. Paes F, Machado S, Arias-Carrion O, et al.: The value of repetitive transcranial magnetic stimulation (rTMS) for the treatment of anxiety disorders: an integrative review. CNS Neurol Disord Drug Targets. 2011, 10:610–620. https://doi.org/10.2174/1871527117962349433

48. Machado S, Arias-Carrion O, Paes F, et al.: Repetitive transcranial magnetic stimulation for clinical applications in neurological and psychiatric disorders: an overview. Eur J Med. 2015, 45:191–206. 10.5152/ejme.2015.39

49. Raymaekers S, Vansteelandt K, Luyten L, Verroes C, Demyttenaere K, Gabriels L, Nuttin B: Long-term electrical stimulation of bed nucleus of stria terminalis for obsessive-compulsive disorder. Mol Psychiatry. 2017, 22:931–934. 10.1038/mp.2016.124

50. Luyck K, Tambuyzer T, Deprez M, Rangarajan J, Nuttin B, Luyten L: Electrical stimulation of the bed nucleus of the stria terminalis reduces anxiety in a rat model. Trans Psychiatry. 2017, 7:1033. 10.1038/tp.2017.2